Acer plummets toward a record low after the Food and Drug Administration declined to approve its treatment for a genetic disorder that can cause blood vessels to fatally rupture.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
The names include a veterinary drug concern plus companies with successful drugs on the market.
These two firms have successful drugs and could make nice additions for larger companies.
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.